New Analysis Finds That FDA Proposed Rule Would Add Billions to Drug Spending
July 2016 -- This updated analysis concludes that the FDA's Proposed Rule to permit generic drug manufacturers to change drug labels would increase generic spending by $5.6 billion in 2017, rising to $8.6 billion in 2024. . . . Read the full study here
New Study Recommends Incentivizing the Use of U.S. Biosimilars
April 2016 -- This study suggests that carefully constructed physician incentives from public and private payors could boost biosimilar utilization, benefiting U.S. patients and the health care system as a whole. . . . Read the full study here
New Paper Highlights Strategies to Foster Home Dialysis in the United States
March 2016 -- This paper identifies barriers to home dialysis and suggests that if these barriers were removed, the resulting increase in home dialysis utilization would send strong signals to innovators to develop new technologies. . . . Read the full report here
- This analysis shows that a robust U.S. biosimilars market for a broad spectrum of biologic products is unlikely but that biosimilar entry for blockbuster biologic products is viable.
- This paper examines how the FDA, within its core mission of ensuring the safety and efficacy of drugs, affects competition in the pharmaceutical industry.
- This study estimates the potential savings, nationally and for the Medicare population, from preventing the development of five comorbidities by reducing obesity rates by 10 percent.